All Stories

  1. Are There Causal Associations Between Obsessive‐Compulsive Disorder and Cardiometabolic Phenotypes? A Genetic Correlation and Bi‐Directional Mendelian Randomization Study
  2. ω-3 Fatty Acids in Pediatric Major Depressive Disorder
  3. Mapping the genetic landscape across 14 psychiatric disorders
  4. Peer victimization in adolescence alters gene expression and cytokine profiles during transition to adulthood
  5. The role of astrocytes in attention-deficit hyperactivity disorder: An update
  6. Assessing the effects of methylphenidate in proliferation and Wnt activity of neuronal stem cells from attention deficit/hyperactivity disorder patients
  7. Polygenic Hazard Score for Predicting Age-associated Risk of Alzheimer’s Disease in European Populations: Development and Validation
  8. Machine learning in Alzheimer’s disease genetics
  9. The link between Wnt-related, stress-related, and circadian genes in the dermal fibroblasts of individuals with attention-deficit hyperactivity disorder
  10. Approaching therapy of Alzheimer’s disease via the antidiabetic drug liraglutide—a study with streptozotocin intracerebroventricularly treated Wistar rats
  11. Thiamine Compounds Alleviate Oxidative Stress, Over-Expression of Pro-Inflammatory Markers and Behavioral Abnormalities in a Mouse Predation Model of PTSD
  12. Ensemblex: an accuracy-weighted ensemble genetic demultiplexing framework for population-scale scRNAseq sample pooling
  13. From stress to anhedonia: differential gene expression, behavioural and biochemical modulations in resilient versus susceptible mice in an ultrasound model of juvenile depression
  14. Transferability of European-derived Alzheimer’s disease polygenic risk scores across multiancestry populations
  15. Genome-wide analyses identify 30 loci associated with obsessive–compulsive disorder
  16. APOEstratified genome-wide association studies provide novel insights into the genetic etiology of Alzheimers’s disease
  17. Genetic susceptibility to schizophrenia through neuroinflammatory pathways associated with retinal thinness
  18. Neurodevelopmental effects of omega-3 fatty acids and its combination with Methylphenidate in iPSC models of ADHD
  19. Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial
  20. Alterations in proliferation of neuronal stem cells in Attention-Deficit/Hyperactivity Disorder and Wnt modulation by methylphenidate
  21. Exploring the interplay of glucose metabolism, insulin resistance, and neurodegenerative pathologies: insights from streptozotocin and hypoglycaemic in vitro models
  22. Investigating the impact of omega-3 fatty acids on oxidative stress and pro-inflammatory cytokine release in iPSC-derived forebrain cortical neurons from ADHD patients
  23. X‐chromosome-wide association study for Alzheimer’s disease
  24. Generation of induced pluripotent stem cells from ADHD patients who do or do not respond to Methylphenidate treatment
  25. Extremely rare CNVs contributing to Alzheimer disease risk: a case-control association analysis of exome sequencing data from 22,319 individuals
  26. Peer victimization in adolescence alters gene expression and cytokine profiles during transition to adulthood
  27. A genome‐wide association meta‐analysis of all‐cause and vascular dementia
  28. Ensemblex: an accuracy-weighted ensemble genetic demultiplexing framework for population-scale scRNAseq sample pooling
  29. Ensemblex: an accuracy-weighted ensemble genetic demultiplexing framework for population-scale scRNAseq sample pooling
  30. Correspondence to “Bipolar disorder-iPSC derived neural progenitor cells exhibit dysregulation of store-operated Ca2+ entry and accelerated differentiation” by Hewitt et al. (PMID: 37402854)
  31. Long non-coding RNAs H19 and NKILA are associated with the risk of death and lacunar stroke in the elderly population
  32. Genetic susceptibility to schizophrenia through neuroinflammatory pathways is associated with retinal thinning: Findings from the UK-Biobank
  33. Stress as a mediator of brain alterations in attention-deficit hyperactivity disorder: A systematic review
  34. Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder
  35. Correction: White matter diffusion estimates in obsessive-compulsive disorder across 1653 individuals: machine learning findings from the ENIGMA OCD Working Group
  36. White matter diffusion estimates in obsessive-compulsive disorder across 1653 individuals: machine learning findings from the ENIGMA OCD Working Group
  37. Psychopharmacology in children and adolescents: unmet needs and opportunities
  38. Iron status in Swiss adolescents with paediatric major depressive disorder and healthy controls: a matched case–control study
  39. Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms
  40. An investigation on the alterations in Wnt signaling in ADHD across developmental stages
  41. Is there an intrinsic link between attention-deficit/hyperactivity disorder and Alzheimer's disease? Examination using polygenic risk scores in the UK Biobank
  42. Transferability of European-derived Alzheimer’s Disease Polygenic Risk Scores across Multi-Ancestry Populations
  43. Editorial: Obsessive-compulsive related disorders (OCRD) across the lifespan
  44. Multiancestry analysis of the HLA locus in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes
  45. Executive functions and borderline personality features in adolescents with major depressive disorder
  46. The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications
  47. Generation of induced pluripotent stem cells from two ADHD patients and two healthy controls
  48. Genetic Associations Between Modifiable Risk Factors and Alzheimer Disease
  49. Circulating Long Noncoding RNA Signatures Associate With Incident Diabetes in Older Adults: A Prospective Analysis From the VITA Cohort Study
  50. Circulating long noncoding RNA signatures associate with incident diabetes in older adults: a prospective analysis from the VITA cohort study
  51. Circulating long noncoding RNA signatures associate with incident diabetes in older adults: a prospective analysis from the VITA cohort study
  52. Growth rates of human induced pluripotent stem cells and neural stem cells from attention-deficit hyperactivity disorder patients: a preliminary study
  53. From attention-deficit hyperactivity disorder to sporadic Alzheimer’s disease—Wnt/mTOR pathways hypothesis
  54. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
  55. Elucidating the functional effects of omega-3 fatty acids as a treatment in ADHD against inflammation and oxidative stress
  56. Involvement of the WNT signalling in methylphenidate (ritalin) treatment of attention deficit hyperactivity disorder
  57. Protocol for a Wnt reporter assay to measure its activity in human neural stem cells derived from induced pluripotent stem cells
  58. Recommendations, guidelines, and best practice for the use of human induced pluripotent stem cells for neuropharmacological studies of neuropsychiatric disorders
  59. Advances in problematic usage of the internet research – A narrative review by experts from the European network for problematic usage of the internet
  60. A review of the genetic basis of problematic Internet use
  61. Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease
  62. Protective association of HLA-DRB1*04 subtypes in neurodegenerative diseases implicates acetylated tau PHF6 sequences
  63. Brain-derived neurotrophic factor protects serotonergic neurons against 3,4-methylenedioxymethamphetamine (“Ecstasy”) induced cytoskeletal damage
  64. New insights into the genetic etiology of Alzheimer’s disease and related dementias
  65. Media use and emotional distress under COVID-19 lockdown in a clinical sample referred for internalizing disorders: A Swiss adolescents' perspective
  66. Problematic use of the internet during the COVID-19 pandemic: Good practices and mental health recommendations
  67. Promising Developments in the Use of Induced Pluripotent Stem Cells in Research of ADHD
  68. Elucidating the functional effects of omega-3 fatty acids as a treatment in ADHD against Wnt-signalling alterations
  69. Protective association of HLA-DRB1*04 subtypes in neurodegenerative diseases implicates acetylated Tau PHF6 sequences
  70. P.0006 BDNF levels in blood serum and plasma of MDMA users and MDMA-naïve controls
  71. P.0025 Preliminary results of growth rate profiling of induced pluripotent stem cells and neuronal progenitor cells from Attention-Deficit Hyperactivity Disorder
  72. Polygenic risk scores across the extended psychosis spectrum
  73. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects
  74. Genome-wide association study identifies new locus associated with OCD
  75. Media use before, during and after COVID-19 lockdown according to parents in a clinically referred sample in child and adolescent psychiatry: Results of an online survey in Switzerland
  76. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
  77. Generation of integration-free induced pluripotent stem cell lines from four pediatric ADHD patients
  78. Generation of integration-free induced pluripotent stem cells from healthy individuals
  79. The Interplay Between Postsynaptic Striatal D2/3 Receptor Availability, Adversity Exposure and Odd Beliefs: A [11C]-Raclopride PET Study
  80. Genome-wide association study of pediatric obsessive-compulsive traits: shared genetic risk between traits and disorder
  81. Genetics of OCD and Related Disorders; Searching for Shared Factors
  82. New insights on the genetic etiology of Alzheimer’s and related dementia
  83. The stress–Wnt-signaling axis: a hypothesis for attention-deficit hyperactivity disorder and therapy approaches
  84. Preventing problematic internet use during the COVID-19 pandemic: Consensus guidance
  85. ADHD: Current Concepts and Treatments in Children and Adolescents
  86. Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders
  87. An overview of the first 5 years of the ENIGMA obsessive–compulsive disorder working group: The power of worldwide collaboration
  88. Psychiatric symptoms and expression of glucocorticoid receptor gene in cocaine users: A longitudinal study
  89. Profiling parvalbumin interneurons using iPSC: challenges and perspectives for Autism Spectrum Disorder (ASD)
  90. Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings
  91. Genetics of obsessive-compulsive disorder and Tourette disorder
  92. High-resolution chromosomal microarray analysis for copy-number variations in high-functioning autism reveals large aberration typical for intellectual disability
  93. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders
  94. Genome-wide Association Study of Pediatric Obsessive-Compulsive Traits: Shared Genetic Risk between Traits and Disorder
  95. Omega-3 Fatty Acids as a Treatment for Pediatric Depression. A Phase III, 36 Weeks, Multi-Center, Double-Blind, Placebo-Controlled Randomized Superiority Study
  96. Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brain‐related functional pathways
  97. Common variants in Alzheimer's disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores
  98. Influence of oxytocin receptor single nucleotide sequence variants on contractility of human myometrium: an in vitro functional study
  99. New insights and perspectives on the genetics of obsessive-compulsive disorder
  100. No Association of Variants of the NPY-System With Obsessive-Compulsive Disorder in Children and Adolescents
  101. Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice
  102. Association study and a systematic meta-analysis of the VNTR polymorphism in the 3′-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder
  103. Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity – a consensus of the Biomarkers Task Force from the WFSBP
  104. Astrocyte- and Microglia-Specific Mitochondrial DNA Deletions Levels in Sporadic Alzheimer’s Disease
  105. The involvement of the canonical Wnt-signaling receptor LRP5 and LRP6 gene variants with ADHD and sexual dimorphism: Association study and meta-analysis
  106. Manifesto for a European research network into Problematic Usage of the Internet
  107. Improved Generation of Induced Pluripotent Stem Cells From Hair Derived Keratinocytes – A Tool to Study Neurodevelopmental Disorders as ADHD
  108. Comment on the global gaming industry's statement on ICD-11 gaming disorder: a corporate strategy to disregard harm and deflect social responsibility?
  109. Glucocorticoid receptor gene variants and lower expression of NR3C1 are associated with cocaine use
  110. Neuregulin 1 (NRG1) gene expression predicts functional outcomes in individuals at clinical high-risk for psychosis
  111. Methylphenidate enhances neuronal differentiation and reduces proliferation concomitant to activation of Wnt signal transduction pathways
  112. Neurochemical markers as potential indicators of postmortem tissue quality
  113. Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits
  114. Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson’s Disease Substantia Nigra
  115. A pilot investigation on DNA methylation modifications associated with complex posttraumatic symptoms in elderly traumatized in childhood
  116. High resolution chromosomal microarray analysis in paediatric obsessive-compulsive disorder
  117. Controversial Effects of D-Amino Acid Oxidase Activator (DAOA)/G72 on D-Amino Acid Oxidase (DAO) Activity in Human Neuronal, Astrocyte and Kidney Cell Lines: The N-methyl D-aspartate (NMDA) Receptor Hypofunction Point of View
  118. Integrating evolutionary and regulatory information with a multispecies approach implicates genes and pathways in obsessive-compulsive disorder
  119. Explorative results from multistep screening for potential genetic risk loci of Alzheimer’s disease in the longitudinal VITA study cohort
  120. The impact of methylphenidate and its enantiomers on dopamine synthesis and metabolism in vitro
  121. Combining genetic and epigenetic parameters of the serotonin transporter gene in obsessive-compulsive disorder
  122. A systematic meta-analysis of the association of Neuregulin 1 (NRG1), d-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia
  123. Effects of oxytocin and arginine vasopressin on the proliferation and differentiation of a serotonergic cell line
  124. The diabetic brain and cognition
  125. Revealing the complex genetic architecture of obsessive–compulsive disorder using meta-analysis
  126. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease
  127. A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects
  128. Emerging role of miRNA in attention deficit hyperactivity disorder: a systematic review
  129. Expression of D-Amino Acid Oxidase (DAO/DAAO) and D-Amino Acid Oxidase Activator (DAOA/G72) during Development and Aging in the Human Post-mortem Brain
  130. The hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride activates neurotrophin receptors in a neuronal cell line and promotes neurites extension
  131. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson’s disease
  132. Neuregulin-1, D-amino acid oxidase and D-amino acid oxidase activator polymorphisms in individuals at-risk for psychosis
  133. DNA methylation profiles of elderly individuals subjected to indentured childhood labor and trauma
  134. Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms
  135. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition
  136. Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics
  137. REGION-SPECIFIC REGULATION OF THE SEROTONIN 2A RECEPTOR EXPRESSION IN DEVELOPMENT AND AGING IN POSTMORTEM HUMAN BRAIN
  138. CNTNAP2 gene in high functioning autism: no association according to family and meta-analysis approaches
  139. α2A -Adrenergic receptor polymorphisms and mRNA expression levels are associated with delay discounting in cocaine users
  140. Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction
  141. Serotonin Transporter and Tryptophan Hydroxylase Gene Variations Mediate Working Memory Deficits of Cocaine Users
  142. Region-specific regulation of the serotonin 2A receptor expression in development and ageing inpost mortemhuman brain
  143. Was können Biomarker heute leisten? Über den Einsatz von Biomarkern in der psychiatrischen Diagnostik am Beispiel der ADHS
  144. Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer’s disease progression: CX3CL1, TREM2, and PPARγ
  145. Cross-Disorder Genome-Wide Analyses Suggest a Complex Genetic Relationship Between Tourette’s Syndrome and OCD
  146. Neurotrophin blood-based gene expression and social cognition analysis in patients with autism spectrum disorder
  147. Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer’s disease
  148. Was sind Omics?
  149. Prenatal stress increases the striatal and hippocampal expression of correlating c-FOS and serotonin transporters in murine offspring
  150. Aldehyde dehydrogenase (ALDH) in Alzheimer’s and Parkinson’s disease
  151. Imaging genetics in obsessive-compulsive disorder: Linking genetic variations to alterations in neuroimaging
  152. P.1.g.071 Interaction between serotonin 1A and 2A receptor subtypes in neuronal and lymphoblastoid cells
  153. Trio study and meta-analysis support the association of genetic variation at the serotonin transporter with early-onset obsessive–compulsive disorder
  154. Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study
  155. Real-Time Impedance-based Cell Analyzer as a Tool to Delineate Molecular Pathways Involved in Neurotoxicity and Neuroprotection in a Neuronal Cell Line
  156. Real-Time Impedance-based Cell Analyzer as a Tool to Delineate Molecular Pathways Involved in Neurotoxicity and Neuroprotection in a Neuronal Cell Line
  157. Copy Number Variation in Obsessive-Compulsive Disorder and Tourette Syndrome: A Cross-Disorder Study
  158. The neurobiological link between OCD and ADHD
  159. Wie biologisch sind Zwangsstörungen?
  160. Neuron-Specific Alterations in Signal Transduction Pathways associated with Alzheimer's Disease
  161. Extraordinarily Fast Response to Low-Dose Sertraline in a Child with Severe Obsessive-Compulsive Disorder and High Functioning Serotonin Transporter Genotype
  162. Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder
  163. Investigation of association of serotonin transporter and monoamine oxidase-A genes with Alzheimer's disease and depression in the VITA study cohort: A 90-month longitudinal study
  164. Aldehyde dehydrogenase 2 in sporadic Parkinson's disease
  165. Association study in siblings and case-controls of serotonin- and oxytocin-related genes with high functioning autism
  166. Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene
  167. Enhancement of cell viability after treatment with polyunsaturated fatty acids
  168. Neuron-Specific Mitochondrial DNA Deletion Levels in Sporadic Alzheimer´s Disease
  169. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity
  170. The Loudness Dependence of Auditory Evoked Potentials (LDAEP) as an Indicator of Serotonergic Dysfunction in Patients with Predominant Schizophrenic Negative Symptoms
  171. 5-HT2A serotonin receptor agonist DOI alleviates cytotoxicity in neuroblastoma cells: Role of the ERK pathway
  172. Manifesto for a European research network into obsessive-compulsive and related disorders
  173. Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?
  174. Correction: Methylphenidate enhances neural stem cell differentiation
  175. Methylphenidate enhances neural stem cell differentiation
  176. S.08.03 New findings of copy number variations in OCD
  177. S.08.01 Potential biomarkers and genetic findings in ADHD
  178. Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study
  179. In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder
  180. Editorial
  181. Different effects of soluble and aggregated amyloid β42 on gene/protein expression and enzyme activity involved in insulin and APP pathways
  182. Pilot study: potential transcription markers for adult attention-deficit hyperactivity disorder in whole blood
  183. Alzheimer's disease and type 2 diabetes: Two diseases, one common link?
  184. Parkinson's disease: Molecular risk factors
  185. Inflammatory Pathways in Parkinson’s Disease; A BNE Microarray Study
  186. A molecular signature in blood identifies early Parkinson’s disease
  187. 1.12.1 PARKINSON'S DISEASE: MOLECULAR RISK FACTORS
  188. Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzymegene
  189. Altered mRNA expression of monoaminergic candidate genes in the blood of children with attention deficit hyperactivity disorder and autism spectrum disorder
  190. Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimer’s disease: The VITA and Milano studies
  191. d/l threo-methylphenidate enantiomers influence on catecholaminergic enzyme activities
  192. Pilot study on HTR2A promoter polymorphism, −1438G/A (rs6311) and a nearby copy number variation showed association with onset and severity in early onset obsessive–compulsive disorder
  193. Correlation of cognitive deficits and brain cholinesterase activity in streptozotocin-intracerebroventricularly treated rat model of sporadic alzheimer's disease
  194. Editorial
  195. Association of a Functional NOS1 Promoter Repeat with Alzheimer's Disease in the VITA Cohort
  196. Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats
  197. Brain tryptophan rather than pH-value is altered as consequence of artificial postmortem interval and storage conditions
  198. Alteration of the pro-oxidant xanthine oxidase (XO) in the thalamus and occipital cortex of patients with schizophrenia
  199. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease
  200. Effects of methylphenidate: the cellular point of view
  201. PGC-1 , A Potential Therapeutic Target for Early Intervention in Parkinson's Disease
  202. Methyl- and acetyltransferases are stable epigenetic markers postmortem
  203. The link between iron, metabolic syndrome, and Alzheimer’s disease
  204. Diabetes Type II: A Risk Factor for Depression–Parkinson–Alzheimer?
  205. Increased Mitochondrial Aldehydedehydrogenase in the putamen of individuals with Alzheimer's disease
  206. Increased xanthine oxidase in the thalamus and putamen in depression
  207. Genetics of early-onset obsessive–compulsive disorder
  208. Can enzyme kinetics of prooxidants teach us a lesson about the treatment of Alzheimer's disease: A pilot post-mortem study
  209. Chronic exogenous corticosterone administration generates an insulin-resistant brain state in rats
  210. Modeling Sporadic Alzheimer's Disease: The Insulin Resistant Brain State Generates Multiple Long-Term Morphobiological Abnormalities Including Hyperphosphorylated Tau Protein and Amyloid-β
  211. Tryptophan is a marker of human postmortem brain tissue quality
  212. P.1.d.01l Multilevel phenotyping of NOS-I knockdown mice
  213. Stress and methylphenidate treatment, both modulate neuronal activity in an animal model for ADHD
  214. Potential gene expression biomarkers in whole blood of Alzheimer's disease
  215. pH measurement as quality control on humanpost mortembrain tissue: a study of the BrainNet Europe consortium
  216. Gene Expression as Peripheral Biomarkers for Sporadic Alzheimer's Disease
  217. Genetic risk factors and markers for Alzheimer’s disease and/or depression in the VITA study
  218. Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers
  219. Trabalho de consenso de força-tarefa da WFSBP sobre marcadores biológicos das demências: contribuição da análise do LCR e do sangue para o diagnóstico precoce e diferencial das demências
  220. Commonalities in the genetics of Alzheimer’s disease and Parkinson’s disease
  221. Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: A comparative post-mortem study
  222. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements
  223. P1-347: Biomarkers for Alzheimer's disease and depression in the Vienna Transdanube Aging (VITA) study
  224. Genomic aspects of sporadic Parkinson's disease
  225. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
  226. Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC-70
  227. Increased xanthine oxidase in the thalamus and putamen in depression
  228. Comparison Analysis of Gene Expression Patterns between Sporadic Alzheimer's and Parkinson's Disease
  229. The effect of methylphenidate treatment on the expression of synaptic vesicle proteins in a mouse model for Attention-Deficit/Hyperactivity Disorder
  230. Methylphenidate effects on cell growth and maturation in neuronal stem cells
  231. Alterations in Expression of Glutamatergic Transporters and Receptors in Sporadic Alzheimer's Disease
  232. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein
  233. Genes and Oxidative Stress in Sporadic and Familial Parkinsonism: cDNA Microarray Studies
  234. Gene and Protein Expression Profiling in Parkinson's Disease: Quest for Neuroprotective Drugs
  235. HIV Dementia: A Neurodegenerative Disorder with Viral Etiology
  236. 1.011 Early diagnosis for Parkinson's disease according to whole blood gene profile
  237. 1.100 Early diagnosis for Parkinson's disease according to whole blood gene profile
  238. Biostatistical analysis of gene microarrays reveals diverse expression clusters between macaque subspecies in brain SIV infection
  239. Association study of BDNF and CNTF polymorphism to depression in non-demented subjects of the “VITA” study
  240. Insulin resistant brain state: behavioural, neurochemical and genetical resemblance to sporadic Alzheimer's disease
  241. Estrogen Receptor ?? Gene (ESR??) 3???-UTR Variants in Alzheimer Disease
  242. Association Study of the 5-HTTLPR Polymorphism and Depression in 75-Year-Old Nondemented Subjects From the Vienna Transdanube Aging (VITA) Study
  243. Serotonin transporter polymorphism and LDL-cholesterol
  244. Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat
  245. The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice
  246. Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes
  247. Neuroprotective Strategies in Parkinson's Disease Using the Models of 6-Hydroxydopamine and MPTPa
  248. Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation
  249. Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC-70
  250. Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia
  251. Oxidative stress related markers in the “VITA” and the centenarian projects
  252. Genexpressionanalysen von Substantia-nigra-Gewebe Parkinson-Kranker
  253. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes
  254. Gene expression profile in streptozotocin rat model for sporadic Alzheimer?s disease
  255. The benefits of microarrays as tools for studying neuropsychiatric disorders
  256. Symposia
  257. Monoamine Oxidase-B Inhibition in Alzheimer's Disease
  258. Neuroprotective Strategies in Parkinson???s Disease
  259. Free radicals in Parkinson's disease
  260. Early and late molecular events in neurodegeneration and neuroprotection in Parkinson’s disease MPTP model as assessed by cDNA microarray; the role of iron
  261. Monoamin-Oxidase-Hemmer
  262. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine
  263. Molecular events in dopaminergic neurodegeneration and neuroprotection in MPTP model of Parkinson’s disease employing cDNA microarray Silvia Mandel, Edna Grünblatt, Yona Levites, Gila Maor, Moussa BH Youdim
  264. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
  265. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies
  266. Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for Neuroprotection
  267. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson’s disease
  268. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine
  269. The Pivotal Role of Iron in NF-kappaB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators
  270. Apomorphine protects against MPTP-induced neurotoxicity in mice
  271. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity
  272. A hierarchical approach to vegetation classification in Kenya
  273. Behavioural and expressional phenotyping of nitric oxide synthase-I knockdown animals